Eton Pharmaceuticals (ETON) Return on Capital Employed (2018 - 2025)
Eton Pharmaceuticals (ETON) reported Return on Capital Employed of 1.41% for Q4 2025, up 580.0% on a YoY basis from 0.21% in Q4 2024, and up 68.98% sequentially from 4.55% in Q3 2025.
Eton Pharmaceuticals (ETON) Return on Capital Employed (2018 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 8 years of Return on Capital Employed data on file, last reported at 1.41% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 580.0% year-over-year to 1.41%; the trailing twelve-month figure through Dec 2025 stood at 1.41% (up 580.0% YoY), and the FY2025 full-year result was 1.85%, up 579.0% from the prior year.
- Return on Capital Employed advanced to 1.41% in Q4 2025, from 4.55% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 8.94% in Q3 2023 to a low of 56.76% in Q2 2022.
- A 5-year average of 24.1% and a median of 20.67% in 2023 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 18434 bps in 2021 and tumbled 4596 bps in 2024, its largest moves.
- Tracing ETON's Return on Capital Employed over 5 years: stood at 6.65% in 2021, then sank by 639 bps to 49.13% in 2022, then surged by 84 bps to 7.74% in 2023, then advanced by 7 bps to 7.21% in 2024, then surged by 80 bps to 1.41% in 2025.
- Business Quant data shows ETON's Return on Capital Employed at 1.41% in Q4 2025, 4.55% in Q3 2025, and 1.49% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 21.43% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.24% |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn | -1.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.41% |
| Sep 30, 2025 | -4.55% |
| Jun 30, 2025 | -1.49% |
| Mar 31, 2025 | -4.14% |
| Dec 31, 2024 | -7.21% |
| Sep 30, 2024 | -37.02% |
| Jun 30, 2024 | -47.94% |
| Mar 31, 2024 | 3.39% |
| Dec 31, 2023 | -7.74% |
| Sep 30, 2023 | 8.94% |
| Jun 30, 2023 | -2.71% |
| Mar 31, 2023 | -33.60% |
| Dec 31, 2022 | -49.13% |
| Sep 30, 2022 | -45.44% |
| Jun 30, 2022 | -56.76% |
| Mar 31, 2022 | -54.67% |
| Dec 31, 2021 | -6.65% |
| Sep 30, 2021 | -44.68% |
| Jun 30, 2021 | -38.83% |
| Mar 31, 2021 | -50.35% |